CC
REGN icon

Cannell & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Cannell & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$9.43M Sell
10,742
-175
-2% -$144K 0.3% 77
2023
Q3 		$8.98M Sell
10,917
-10
-0.1% -$7.86K 0.31% 81
2023
Q2 		$7.85M Buy
10,927
+80
+0.7% +$61.7K 0.26% 92
2023
Q1 		$8.91M Sell
10,847
-1,431
-12% -$1.08M 0.32% 84
2022
Q4 		$8.86M Buy
12,278
+23
+0.2% +$17K 0.32% 82
2022
Q3 		$8.44M Sell
12,255
-33
-0.3% -$20.8K 0.32% 81
2022
Q2 		$7.26M Sell
12,288
-202
-2% -$131K 0.26% 91
2022
Q1 		$8.72M Sell
12,490
-65
-0.5% -$41.1K 0.26% 94
2021
Q4 		$7.93M Sell
12,555
-535
-4% -$329K 0.22% 98
2021
Q3 		$7.92M Buy
13,090
+89
+0.7% +$55.3K 0.24% 98
2021
Q2 		$7.26M Sell
13,001
-5
-0% -$2.53K 0.22% 101
2021
Q1 		$6.15M Sell
13,006
-9,700
-43% -$4.72M 0.19% 108
2020
Q4 		$11M Buy
22,706
+9,461
+71% +$5.11M 0.36% 76
2020
Q3 		$7.41M Buy
13,245
+299
+2% +$181K 0.27% 86
2020
Q2 		$8.07M Sell
12,946
-22,276
-63% -$12.6M 0.32% 72
2020
Q1 		$17.2M Sell
35,222
-431
-1% -$178K 0.83% 40
2019
Q4 		$13.7M Buy
35,653
+23,857
+202% +$8.03M 0.49% 69
2019
Q3 		$3.27M Sell
11,796
-4,985
-30% -$1.48M 0.12% 118
2019
Q2 		$5.25M Sell
16,781
-21,177
-56% -$7.05M 0.2% 102
2019
Q1 		$15.6M Sell
37,958
-6,869
-15% -$2.83M 0.6% 62
2018
Q4 		$16.7M Sell
44,827
-1,036
-2% -$379K 0.73% 47
2018
Q3 		$18.5M Buy
45,863
+13,147
+40% +$5M 0.66% 54
2018
Q2 		$11.3M Buy
32,716
+31,736
+3,238% +$9.93M 0.42% 69
2018
Q1 		$337K Buy
+980
New +$341K 0.01% 213

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Cannell & Co's REGN Position: Q4 2023 in Review

Cannell & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 1.6% in Q4 2023, selling an estimated $144K and leaving 10,742 shares worth $9.43M. The position accounts for 0.3% of the portfolio, ranked #77.

Cannell & Co first reported a position in REGN in Q1 2018 and has held it in 24 quarters since. The position peaked at $18.5M in Q3 2018. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

  • Cannell & Co held 10,742 shares of Regeneron Pharmaceuticals worth $9.43M as of Q4 2023.
  • Cannell & Co sold 175 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $144K.
  • Regeneron Pharmaceuticals made up 0.3% of Cannell & Co's portfolio in Q4 2023, its #77 holding.
  • Cannell & Co first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 24 quarters since.
  • Cannell & Co's Regeneron Pharmaceuticals position peaked at $18.5M in Q3 2018.
  • 1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Cannell & Co's 13F filing for Q4 2023, filed 5 Feb 2024.